Who is who in Grifols, the pharmaceutical company that acted as a bank for the Catalan family. The tangle of interconnections that exist between the family, its company and the investment company of which they are part, Scranton, makes the work of analysts difficult.
The market is awaiting the verdict of the National Securities Market Commission (CNMV), which is interpreted as the final blow for the company in the event that it is not favorable. The problem that Daniel Yu's signature with his reports put on the table remains unresolved: the ties that unite the entire family network.